ID: ALA4873682

Max Phase: Preclinical

Molecular Formula: C38H48F2N5O3+

Molecular Weight: 660.83

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC[N+]1(CCCCCCCOc2cc(C)cc(-n3cc(C(=O)Nc4cc(F)cc(F)c4)c(=O)c4ccc(N(C)C)nc43)c2)CCCCC1

Standard InChI:  InChI=1S/C38H47F2N5O3/c1-5-45(17-11-9-12-18-45)16-10-7-6-8-13-19-48-32-21-27(2)20-31(25-32)44-26-34(38(47)41-30-23-28(39)22-29(40)24-30)36(46)33-14-15-35(43(3)4)42-37(33)44/h14-15,20-26H,5-13,16-19H2,1-4H3/p+1

Standard InChI Key:  WSAPRQRSPMYCDK-UHFFFAOYSA-O

Associated Targets(Human)

COL1A1 promoter (117 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SMAD3 Tchem Mothers against decapentaplegic homolog 2/homolog 3 (10 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SMAD3 Tchem Mothers against decapentaplegic homolog 3 (68039 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK2 Tclin Tyrosine-protein kinase JAK2 (12915 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 660.83Molecular Weight (Monoisotopic): 660.3720AlogP: 7.64#Rotatable Bonds: 14
Polar Surface Area: 76.46Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.56CX Basic pKa: 3.22CX LogP: 4.21CX LogD: 4.21
Aromatic Rings: 4Heavy Atoms: 48QED Weighted: 0.11Np Likeness Score: -1.14

References

1. Lu ZN, Shan Q, Hu SJ, Zhao Y, Zhang GN, Zhu M, Yu DK, Wang JX, He HW..  (2021)  Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways.,  49  [PMID:34610571] [10.1016/j.bmc.2021.116438]

Source